JP2018203766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018203766A5 JP2018203766A5 JP2018166053A JP2018166053A JP2018203766A5 JP 2018203766 A5 JP2018203766 A5 JP 2018203766A5 JP 2018166053 A JP2018166053 A JP 2018166053A JP 2018166053 A JP2018166053 A JP 2018166053A JP 2018203766 A5 JP2018203766 A5 JP 2018203766A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- snag
- bacterial
- snag nanofiber
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002121 nanofiber Substances 0.000 claims 79
- 239000000203 mixture Substances 0.000 claims 77
- 230000001580 bacterial effect Effects 0.000 claims 40
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 30
- 241000191967 Staphylococcus aureus Species 0.000 claims 27
- 238000000338 in vitro Methods 0.000 claims 24
- 230000004083 survival effect Effects 0.000 claims 24
- 208000035143 Bacterial infection Diseases 0.000 claims 20
- 208000022362 bacterial infectious disease Diseases 0.000 claims 20
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 15
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 15
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 15
- -1 N-acetylglucosamine monosaccharide Chemical class 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 239000000835 fiber Substances 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 12
- 230000035755 proliferation Effects 0.000 claims 12
- 238000011200 topical administration Methods 0.000 claims 12
- 208000015181 infectious disease Diseases 0.000 claims 10
- 206010052428 Wound Diseases 0.000 claims 9
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 4
- 241000186359 Mycobacterium Species 0.000 claims 4
- 230000001747 exhibiting effect Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 241000894007 species Species 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 2
- 241000588832 Bordetella pertussis Species 0.000 claims 2
- 241000589969 Borreliella burgdorferi Species 0.000 claims 2
- 241000589567 Brucella abortus Species 0.000 claims 2
- 241001509299 Brucella canis Species 0.000 claims 2
- 241001148106 Brucella melitensis Species 0.000 claims 2
- 241001148111 Brucella suis Species 0.000 claims 2
- 241000589875 Campylobacter jejuni Species 0.000 claims 2
- 201000005019 Chlamydia pneumonia Diseases 0.000 claims 2
- 241000606153 Chlamydia trachomatis Species 0.000 claims 2
- 241000193155 Clostridium botulinum Species 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 241000194031 Enterococcus faecium Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 241000589602 Francisella tularensis Species 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 2
- 241000590002 Helicobacter pylori Species 0.000 claims 2
- 241000589248 Legionella Species 0.000 claims 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 2
- 241000589902 Leptospira Species 0.000 claims 2
- 241000589929 Leptospira interrogans Species 0.000 claims 2
- 241000186779 Listeria monocytogenes Species 0.000 claims 2
- 241000186362 Mycobacterium leprae Species 0.000 claims 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 2
- 241000607760 Shigella sonnei Species 0.000 claims 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims 2
- 241000193985 Streptococcus agalactiae Species 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims 2
- 241000589884 Treponema pallidum Species 0.000 claims 2
- 241000607479 Yersinia pestis Species 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 229940065181 bacillus anthracis Drugs 0.000 claims 2
- 229940056450 brucella abortus Drugs 0.000 claims 2
- 229940038698 brucella melitensis Drugs 0.000 claims 2
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 2
- 208000002925 dental caries Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 238000007922 dissolution test Methods 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 229940023064 escherichia coli Drugs 0.000 claims 2
- 229940118764 francisella tularensis Drugs 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 238000001631 haemodialysis Methods 0.000 claims 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims 2
- 210000003780 hair follicle Anatomy 0.000 claims 2
- 229940037467 helicobacter pylori Drugs 0.000 claims 2
- 230000000322 hemodialysis Effects 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 210000002200 mouth mucosa Anatomy 0.000 claims 2
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 229940115939 shigella sonnei Drugs 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 229940030998 streptococcus agalactiae Drugs 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 229940076156 streptococcus pyogenes Drugs 0.000 claims 2
- 210000003606 umbilical vein Anatomy 0.000 claims 2
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 206010011409 Cross infection Diseases 0.000 claims 1
- 241000238424 Crustacea Species 0.000 claims 1
- 208000035874 Excoriation Diseases 0.000 claims 1
- 206010016936 Folliculitis Diseases 0.000 claims 1
- 208000005422 Foreign-Body reaction Diseases 0.000 claims 1
- 206010017964 Gastrointestinal infection Diseases 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 claims 1
- 238000000134 MTT assay Methods 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 206010029803 Nosocomial infection Diseases 0.000 claims 1
- 208000025157 Oral disease Diseases 0.000 claims 1
- 208000009344 Penetrating Wounds Diseases 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010041899 Stab wound Diseases 0.000 claims 1
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 208000019836 digestive system infectious disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 208000024693 gingival disease Diseases 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000037323 metabolic rate Effects 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 208000030194 mouth disease Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32465710P | 2010-04-15 | 2010-04-15 | |
| US61/324,657 | 2010-04-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095328A Division JP6400628B2 (ja) | 2010-04-15 | 2016-05-11 | ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018203766A JP2018203766A (ja) | 2018-12-27 |
| JP2018203766A5 true JP2018203766A5 (OSRAM) | 2019-02-14 |
| JP6761453B2 JP6761453B2 (ja) | 2020-09-23 |
Family
ID=44799052
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505181A Withdrawn JP2013523898A (ja) | 2010-04-15 | 2011-04-15 | ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 |
| JP2016095328A Active JP6400628B2 (ja) | 2010-04-15 | 2016-05-11 | ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 |
| JP2018166053A Expired - Fee Related JP6761453B2 (ja) | 2010-04-15 | 2018-09-05 | ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505181A Withdrawn JP2013523898A (ja) | 2010-04-15 | 2011-04-15 | ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 |
| JP2016095328A Active JP6400628B2 (ja) | 2010-04-15 | 2016-05-11 | ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US8858964B2 (OSRAM) |
| EP (1) | EP2563371A4 (OSRAM) |
| JP (3) | JP2013523898A (OSRAM) |
| KR (1) | KR101883797B1 (OSRAM) |
| CN (2) | CN107412772A (OSRAM) |
| AU (1) | AU2011239466B2 (OSRAM) |
| BR (1) | BR112012025844A2 (OSRAM) |
| CA (1) | CA2796068C (OSRAM) |
| IL (1) | IL222375A (OSRAM) |
| MX (1) | MX342912B (OSRAM) |
| NZ (2) | NZ703163A (OSRAM) |
| WO (1) | WO2011130646A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3000487B8 (en) | 2007-02-19 | 2022-06-15 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| CN107412772A (zh) | 2010-04-15 | 2017-12-01 | 海洋聚合物技术公司 | 聚‑n‑乙酰葡萄糖胺纳米纤维的抗菌应用 |
| CA2832859C (en) | 2011-04-15 | 2020-06-16 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acetylglucosamine nanofibers |
| CA2850366A1 (en) * | 2011-09-30 | 2013-04-04 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for detection of defensins in a patient sample |
| US10124051B2 (en) * | 2012-05-22 | 2018-11-13 | Glaxosmithkline Biologicals Sa | Meningococcus serogroup X conjugate |
| US20150237837A1 (en) * | 2012-06-18 | 2015-08-27 | Duke University | Non-Human Model for Wound Healing |
| WO2014098865A1 (en) | 2012-12-20 | 2014-06-26 | Hill's Pet Nutrition, Inc. | Pattern recognition receptor expression as a measure of systemic health |
| EP2968190B1 (en) | 2013-03-14 | 2018-10-17 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acetylglucosamine nanofibers |
| JP2015048436A (ja) * | 2013-09-03 | 2015-03-16 | 公立大学法人福井県立大学 | 植物の耐病性を向上させる、生物由来キチン質含有物、その使用方法、及びその製造方法 |
| EP3034612A1 (en) | 2014-12-16 | 2016-06-22 | Greenaltech, S.L. | Chitin and chitosan producing methods |
| US10500222B2 (en) * | 2015-10-19 | 2019-12-10 | Wayne State University | Compositions and methods relating to treatment of infection |
| CN107460140B (zh) * | 2016-06-02 | 2020-11-13 | 浙江科技学院 | 一种芽孢杆菌hz16中抑制军团菌活性物的制备方法 |
| WO2019046577A1 (en) | 2017-08-31 | 2019-03-07 | Syngulon Sa | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF BACTERIOCIN AND ANTIMICROBIAL PEPTIDES |
| US20210169922A1 (en) * | 2018-05-11 | 2021-06-10 | Marine Polymer Technologies, Inc. | Use of poly-n-acetylglucosamine nanofibers for the treatment of gingival recession |
| BR102021021376A2 (pt) * | 2021-10-25 | 2023-05-09 | União Brasileira De Educação Católica - Ubec | Composição, processo de produção da composição e uso da composição de nanofibras que compreende pva, quitosana, antibiótico e peptídeo de defesa do hospedeiro |
| IT202200004574A1 (it) | 2022-03-10 | 2023-09-10 | Sergio Ammendola | Nanoparticelle di N-acetilglucosammina e loro applicazioni |
| KR102846669B1 (ko) * | 2022-04-14 | 2025-08-13 | 충남대학교산학협력단 | miRNA 24가 봉입된 키토산 나노입자를 유효성분으로 포함하는 에드워드시엘라 피스시시다에 대한 어류용 항생 조성물 |
| CN115671368B (zh) * | 2022-10-28 | 2024-03-22 | 东华大学 | 一种用于生物膜清除的纳米纤维复合贴片及其制备方法 |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1038367A (en) | 1963-05-28 | 1966-08-10 | Beecham Group Ltd | Penicillin derivatives |
| US3988411A (en) | 1974-02-11 | 1976-10-26 | American Cyanamid Company | Spinning and shaping poly-(N-acetyl-D-glucosamine) |
| US3989535A (en) | 1974-02-11 | 1976-11-02 | American Cyanamid Company | Solution of poly(N-acetyl-D-glucosamine) |
| US4068757A (en) | 1976-11-03 | 1978-01-17 | American Cyanamid Company | Chitin derived powder in sterile surgical element package |
| US4195175A (en) | 1978-01-03 | 1980-03-25 | Johnson Edwin L | Process for the manufacture of chitosan |
| JPS55152705A (en) | 1979-05-18 | 1980-11-28 | Mitsubishi Rayon Co Ltd | Preparation of water-soluble alkali chitin |
| JPS56131639A (en) | 1980-03-21 | 1981-10-15 | Kureha Chem Ind Co Ltd | Protein-chitosan composition |
| JPS56133344A (en) | 1980-03-21 | 1981-10-19 | Kureha Chem Ind Co Ltd | Novel composite material |
| US4378017A (en) | 1980-03-21 | 1983-03-29 | Kureha Kagaku Kogyo Kabushiki Kaisha | Composite material of de-N-acetylated chitin and fibrous collagen |
| US4532134A (en) | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
| US4394373A (en) | 1981-04-06 | 1983-07-19 | Malette William Graham | Method of achieving hemostasis |
| US4470397A (en) | 1981-11-11 | 1984-09-11 | Lucas Industries Public Limited Company | Fuel injection pumping apparatus |
| US4605623A (en) | 1982-11-08 | 1986-08-12 | Malette William Graham | Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture |
| JPS5998660A (ja) | 1982-11-26 | 1984-06-07 | House Food Ind Co Ltd | 麺類の乾燥方法 |
| JPS59156770A (ja) | 1983-02-25 | 1984-09-06 | Canon Inc | インパクト型プリンタ |
| JPS58220899A (ja) | 1983-03-22 | 1983-12-22 | 工業技術院長 | キチン系抄造体の製造方法 |
| JPS6025003A (ja) | 1983-07-20 | 1985-02-07 | Shiro Okamura | 光磁気記録装置 |
| US4803168A (en) | 1983-09-01 | 1989-02-07 | Damon Biotech, Inc. | Microencapsulation with polymers |
| US4749620A (en) | 1984-02-15 | 1988-06-07 | Massachusetts Institute Of Technology | Encapsulated active material system |
| JPS60208302A (ja) | 1984-03-31 | 1985-10-19 | Unitika Ltd | キチン成形体の製造方法 |
| JPS60215003A (ja) | 1984-04-10 | 1985-10-28 | Unitika Ltd | キトサン成形体の製造方法 |
| EP0171254B1 (en) | 1984-08-03 | 1991-06-19 | Unitika Ltd. | Shaped chitin body |
| JPH0611810B2 (ja) | 1984-08-23 | 1994-02-16 | ユニチカ株式会社 | 多孔性キチン成形体及びその製造方法 |
| JPS61253065A (ja) | 1985-05-02 | 1986-11-10 | 片倉チツカリン株式会社 | キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法 |
| US4895724A (en) | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
| JPS62288602A (ja) | 1986-06-06 | 1987-12-15 | Agency Of Ind Science & Technol | キトサン変性物粒子の製造方法 |
| ATE144781T1 (de) | 1986-06-06 | 1996-11-15 | Union Carbide Corp | Saure dekristallisierung von hochkristallin chitosan oder teilentacetylierten chitin |
| JPH0441422Y2 (OSRAM) | 1986-10-17 | 1992-09-29 | ||
| JPH0525289Y2 (OSRAM) | 1987-01-21 | 1993-06-25 | ||
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4942129A (en) | 1987-07-28 | 1990-07-17 | Queen's University At Kingston | Multiple membrane microencapsulation |
| US5571821A (en) | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| JPH0532702Y2 (OSRAM) | 1987-10-09 | 1993-08-20 | ||
| JP2560363B2 (ja) | 1987-12-23 | 1996-12-04 | ライオン株式会社 | キチン又はキトサン類の精製法 |
| EP0330106A1 (de) | 1988-02-25 | 1989-08-30 | Akzo Nobel N.V. | Modifizierte Cellulose für biocompatible Dialysemembranen II und Verfahren zu deren Herstellung |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5008116A (en) | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
| DE3903797A1 (de) | 1989-02-09 | 1990-08-16 | Hoechst Ag | Verfahren zur herstellung von aktivierten chitosanen und deren verwendung bei der herstellung von chitosanderivaten |
| JPH0657761B2 (ja) | 1989-02-27 | 1994-08-03 | 富士紡績株式会社 | 多孔質キトサン成形物の製造法 |
| JPH02240101A (ja) | 1989-03-14 | 1990-09-25 | Lion Corp | 硫酸化キトサン誘導体及びその製造方法 |
| EP0390481B1 (en) | 1989-03-23 | 1996-02-28 | Sanyo Chemical Industries Ltd. | Surgical adhesive sheet |
| IT1229167B (it) | 1989-04-10 | 1991-07-22 | Texcontor Ets | Complessi del ferro o di altri metalli con derivati solfonati del chitosano |
| US5071977A (en) | 1989-05-10 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Plaque inhibiting oligosaccharide |
| AU5885690A (en) | 1989-07-11 | 1991-01-17 | Union Carbide Chemicals And Plastics Company Inc. | Emulsions comprising aminopolysaccharides |
| US5116747A (en) | 1989-08-11 | 1992-05-26 | University Of Waterloo | Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate |
| DK0426368T3 (da) | 1989-10-31 | 1995-03-13 | Howmedica | Præparater indeholdende chitinderivater til forebyggelse af adhæsion |
| US5093319A (en) | 1989-10-31 | 1992-03-03 | Pfizer Hospital Products Group, Inc. | Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions |
| JPH064531B2 (ja) | 1990-06-04 | 1994-01-19 | アイセロ化学株式会社 | 大腸崩壊性硬質カプセル |
| US5463022A (en) | 1990-08-17 | 1995-10-31 | Drug Delivery System Institute, Ltd. | N-acetylcarboxymethylchitosan derivatives and process for preparation thereof |
| ATE149545T1 (de) | 1990-08-30 | 1997-03-15 | Warner Lambert Co | Formteile aus einer thermoplastischen stärkeschmelze |
| US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
| JPH04126701U (ja) | 1991-05-13 | 1992-11-18 | 株式会社日立製作所 | 潤滑機能を有する下部軸受 |
| US5382569A (en) | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
| JPH0691819B2 (ja) | 1991-05-27 | 1994-11-16 | 工業技術院長 | デアセチラーゼの製造方法 |
| JP3046099B2 (ja) | 1991-06-19 | 2000-05-29 | ユニチカ株式会社 | キチン又はキトサンの綿状物 |
| CA2072395A1 (en) | 1991-07-01 | 1993-01-02 | John T. Hunt | Bicyclic endothelin analogues |
| JPH0525289A (ja) | 1991-07-19 | 1993-02-02 | Unitika Ltd | キチン成形体の製造法 |
| JPH0532702A (ja) | 1991-08-01 | 1993-02-09 | Unitika Ltd | 細胞接着性キチン |
| JPH0551465A (ja) | 1991-08-23 | 1993-03-02 | Unitika Ltd | 球状キチンの製造方法 |
| US5229123A (en) | 1991-10-09 | 1993-07-20 | Hoffmann-La Roche Inc. | Antifungal agents |
| US5219749A (en) | 1991-10-09 | 1993-06-15 | Institute For Molecular Biology & Biotechnology/Forth | Process for isolating and preparing purified chitin deacetylase |
| US5837747A (en) | 1991-10-29 | 1998-11-17 | Vivorx, Inc. | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
| AU669866B2 (en) | 1991-11-05 | 1996-06-27 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| IL100096A (en) | 1991-11-20 | 1996-03-31 | Univ Ramot | Method for entrapment of active materials in chitosan |
| US5260002A (en) | 1991-12-23 | 1993-11-09 | Vanderbilt University | Method and apparatus for producing uniform polymeric spheres |
| DE4200080A1 (de) | 1992-01-03 | 1993-09-30 | Reinmueller Johannes | Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung |
| JPH05235905A (ja) | 1992-02-21 | 1993-09-10 | Toshiba Corp | Ｃｒｃ演算装置 |
| JPH076126A (ja) | 1992-02-26 | 1995-01-10 | Nec Corp | プロセッサ間バス伝送方式 |
| US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| JPH05271094A (ja) | 1992-03-26 | 1993-10-19 | Fuji Photo Film Co Ltd | カルボキシメチル化キチン誘導体を用いる癌転移抑制剤 |
| US5550110A (en) | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| WO1994003483A1 (en) | 1992-07-30 | 1994-02-17 | Chiron Corporation | Endothelin receptor-binding compounds |
| US5871985A (en) | 1992-09-28 | 1999-02-16 | Brown University Research Foundation | Particulate non cross-linked chitosan core matrices for encapsulated cells |
| TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| US5447505A (en) | 1993-08-04 | 1995-09-05 | Merocel Corporation | Wound treatment method |
| JPH07102458A (ja) | 1993-09-30 | 1995-04-18 | Unitika Ltd | キチンウェブ状物 |
| US5624679A (en) | 1993-12-01 | 1997-04-29 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers |
| US5858350A (en) | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
| US5686115A (en) | 1993-12-01 | 1997-11-11 | Marine Polymer Technologies, Inc. | Poly-β-1→4-N-acetylucosamine copolymer composition with collagen |
| US5846952A (en) | 1993-12-01 | 1998-12-08 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery |
| US6743783B1 (en) | 1993-12-01 | 2004-06-01 | Marine Polymer Technologies, Inc. | Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine |
| US5622834A (en) * | 1993-12-01 | 1997-04-22 | Marine Polymer Technologies, Inc. | Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture |
| US5635493A (en) | 1993-12-01 | 1997-06-03 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics |
| US6063911A (en) | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
| US5811416A (en) | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
| WO1996011927A1 (en) | 1994-10-12 | 1996-04-25 | Abbott Laboratories | Endothelin antagonists |
| TW313568B (OSRAM) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US5658943A (en) | 1995-01-05 | 1997-08-19 | Warner-Lambert Company | Phenylalanine derivatives as endothelin antagonists |
| US5510102A (en) | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
| WO1996039122A1 (en) | 1995-06-06 | 1996-12-12 | Marine Polymer Technologies, Inc. | POLY-β-1→4-N-ACETYLGLUCOSAMINE |
| FR2736835B1 (fr) | 1995-07-17 | 1997-10-10 | Aber Technologies | Pansement pour plaies chroniques, notamment escarres, en gel de chitine |
| AU6603996A (en) | 1995-08-24 | 1997-03-19 | Warner-Lambert Company | Furanone endothelin antagonists |
| WO1997037987A1 (en) | 1996-04-10 | 1997-10-16 | Warner-Lambert Company | Ketoacid endothelin antagonists |
| US5804594A (en) | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
| AU6187898A (en) | 1997-01-30 | 1998-08-25 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| US20030060434A1 (en) | 1997-02-18 | 2003-03-27 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| US6162241A (en) | 1997-08-06 | 2000-12-19 | Focal, Inc. | Hemostatic tissue sealants |
| EP0897914B1 (en) | 1997-08-19 | 2004-05-26 | F. Hoffmann-La Roche Ag | Process for the preparation of 2,5-disubstitued pyridines |
| CA2234936C (en) | 1998-04-17 | 2004-06-29 | Glucogenics Pharmaceuticals Inc. | Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine |
| US6046179A (en) | 1998-04-17 | 2000-04-04 | Murch; Simon | Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine |
| DE19821598A1 (de) | 1998-05-14 | 1999-11-18 | Henkel Kgaa | Verfahren zum Abbau von Biopolymeren |
| TW585762B (en) | 1999-11-11 | 2004-05-01 | Tanabe Seiyaku Co | Pharmaceutical composition for prophylaxis or treatment of inflammatory bowel diseases |
| US7041657B2 (en) | 2001-02-12 | 2006-05-09 | Marine Polymer Technologies Inc. | Compositions and methods for modulation of vascular structure and/or function |
| US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
| US7371403B2 (en) | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
| JP2003128704A (ja) | 2001-10-24 | 2003-05-08 | Matsumoto Shika Univ | キチン・キトサンの低分子化方法及び骨伝導物の製造方法 |
| GB0126923D0 (en) | 2001-11-09 | 2002-01-02 | Procter & Gamble | Chitosan compositions |
| JP2005514352A (ja) | 2001-11-14 | 2005-05-19 | ラルフ ライバック | 自己免疫疾患の治療法 |
| JP3947391B2 (ja) * | 2001-11-28 | 2007-07-18 | 独立行政法人 日本原子力研究開発機構 | 橋かけ構造を有するキチン誘導体及び／又はキトサン誘導体の製造方法 |
| US7037983B2 (en) | 2002-06-14 | 2006-05-02 | Kimberly-Clark Worldwide, Inc. | Methods of making functional biodegradable polymers |
| US20090130186A1 (en) * | 2002-06-14 | 2009-05-21 | Hemcon Medical Technologies, Inc. | Wound dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan and incorporating silver nanoparticles |
| FR2843125B1 (fr) * | 2002-08-02 | 2012-11-16 | Coletica | Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs |
| AU2003263332A1 (en) | 2002-09-11 | 2004-04-30 | Johnson And Johnson Medical Limited | Wound dressings for the treatment of wound infection |
| GB2393120A (en) | 2002-09-18 | 2004-03-24 | Johnson & Johnson Medical Ltd | Compositions for wound treatment |
| US20070237812A1 (en) * | 2006-04-11 | 2007-10-11 | Tyco Healthcare Group | Multi-layer wound dressings |
| JP2006515309A (ja) | 2002-12-31 | 2006-05-25 | マリン ポリマー テクノロジーズ，インコーポレーテッド | 止血剤組成物およびその使用 |
| AU2004214932B2 (en) | 2003-02-24 | 2009-12-03 | Marine Polymer Technologies, Inc. | Cell-polymer fiber compositions and use thereof |
| WO2005027993A2 (en) | 2003-09-12 | 2005-03-31 | Marine Polymer Technologies, Inc. | Vascular access preservation in hemodialysis patients |
| AU2004273738B2 (en) | 2003-09-19 | 2011-02-03 | Otsuka Pharmaceutical Co., Ltd. | Human beta-defensin secretion promoter |
| RU2240830C1 (ru) | 2003-12-26 | 2004-11-27 | ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов | Раневое покрытие и способ его получения |
| US7417037B2 (en) | 2004-01-20 | 2008-08-26 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
| US7780873B2 (en) | 2004-02-23 | 2010-08-24 | Texas A&M University System | Bioactive complexes compositions and methods of use thereof |
| JP2005281239A (ja) | 2004-03-30 | 2005-10-13 | Nippon Zeon Co Ltd | 鶏用ｄｎａワクチン |
| US7704522B2 (en) | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
| CA2487564A1 (en) | 2004-11-12 | 2006-05-12 | Valorisation Recherche Hscm | Folic acid-chitosan-dna nanoparticles |
| DE102004061406A1 (de) | 2004-12-21 | 2006-07-06 | Bayer Innovation Gmbh | Infektionsresistente Polyurethanschäume, Verfahren zu ihrer Herstellung und Verwendung in antiseptisch ausgestatteten Wundauflagen |
| US20070036846A1 (en) * | 2005-08-15 | 2007-02-15 | Tsang Wing W M | Wound dressing and method of manufacture thereof |
| EP1948810A4 (en) | 2005-11-04 | 2010-06-30 | Biosyntech Canada Inc | COMPOSITION AND METHOD USING CHITOSAN FOR THE EFFICIENT ADMINISTRATION OF NUCLEIC ACIDS TO CELLS |
| US8277849B2 (en) | 2006-01-19 | 2012-10-02 | Solazyme, Inc. | Microalgae-derived compositions for improving the health and appearance of skin |
| WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| WO2008039390A2 (en) | 2006-09-22 | 2008-04-03 | Government Of The Usa., Dept. Of Health & Human Services | Compositions and methods for chitosan enhanced immune response |
| US20120156137A1 (en) | 2006-10-20 | 2012-06-21 | Soo-Youl Kim | Composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them |
| KR100882611B1 (ko) | 2006-11-14 | 2009-02-12 | 주식회사 키토라이프 | 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법 |
| KR20090108723A (ko) | 2007-01-31 | 2009-10-16 | 알러간, 인코포레이티드 | 안 약물 송달을 위한 신규한 생체적합물질 및 이의 제조방법 및 용도 |
| EP3000487B8 (en) * | 2007-02-19 | 2022-06-15 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| ES2324192B1 (es) * | 2008-01-30 | 2010-06-17 | PUIG BEAUTY & FASHION GROUP, S.L. | Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas. |
| US8436157B2 (en) | 2008-03-26 | 2013-05-07 | Tate & Lyle Technology Limited | Method for the production of sucralose |
| KR20110031962A (ko) | 2008-07-18 | 2011-03-29 | 노보자임스 아데니움 바이오테크 에이/에스 | 포유류 베타 방어소를 이용한 염증 질환의 치료 |
| US20100086613A1 (en) | 2008-10-03 | 2010-04-08 | Chang-Jer Wu | Chitosan vehicle and method for making same |
| US20100105139A1 (en) | 2008-10-27 | 2010-04-29 | Remco Alexander Spanjaard | Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents |
| CN107412772A (zh) | 2010-04-15 | 2017-12-01 | 海洋聚合物技术公司 | 聚‑n‑乙酰葡萄糖胺纳米纤维的抗菌应用 |
| CA2833415A1 (en) | 2010-05-10 | 2011-11-17 | Corporation De L'ecole Polytechnique De Montreal | Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1 |
| MX358050B (es) | 2010-11-06 | 2018-08-03 | Marine Polymer Tech Inc | Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros. |
| CA2832859C (en) | 2011-04-15 | 2020-06-16 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acetylglucosamine nanofibers |
| JP5496427B2 (ja) | 2011-09-15 | 2014-05-21 | 国立大学法人鳥取大学 | 炎症性腸疾患治療剤 |
| EP2968190B1 (en) | 2013-03-14 | 2018-10-17 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acetylglucosamine nanofibers |
-
2011
- 2011-04-15 CN CN201610880703.7A patent/CN107412772A/zh active Pending
- 2011-04-15 WO PCT/US2011/032709 patent/WO2011130646A1/en not_active Ceased
- 2011-04-15 EP EP11769676.5A patent/EP2563371A4/en not_active Withdrawn
- 2011-04-15 US US13/641,015 patent/US8858964B2/en active Active
- 2011-04-15 BR BR112012025844A patent/BR112012025844A2/pt not_active Application Discontinuation
- 2011-04-15 CN CN201180029320.4A patent/CN103108638B/zh not_active Expired - Fee Related
- 2011-04-15 NZ NZ703163A patent/NZ703163A/en not_active IP Right Cessation
- 2011-04-15 AU AU2011239466A patent/AU2011239466B2/en not_active Ceased
- 2011-04-15 MX MX2012011816A patent/MX342912B/es active IP Right Grant
- 2011-04-15 KR KR1020127029471A patent/KR101883797B1/ko not_active Expired - Fee Related
- 2011-04-15 CA CA2796068A patent/CA2796068C/en active Active
- 2011-04-15 NZ NZ602909A patent/NZ602909A/en not_active IP Right Cessation
- 2011-04-15 JP JP2013505181A patent/JP2013523898A/ja not_active Withdrawn
-
2012
- 2012-10-11 IL IL222375A patent/IL222375A/en active IP Right Grant
-
2014
- 2014-07-09 US US14/327,192 patent/US9198928B2/en active Active
-
2015
- 2015-10-29 US US14/927,372 patent/US9642871B2/en active Active
-
2016
- 2016-05-11 JP JP2016095328A patent/JP6400628B2/ja active Active
-
2017
- 2017-03-31 US US15/476,222 patent/US10206938B2/en active Active
-
2018
- 2018-09-05 JP JP2018166053A patent/JP6761453B2/ja not_active Expired - Fee Related
- 2018-12-21 US US16/230,705 patent/US10561677B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018203766A5 (OSRAM) | ||
| JP2013523898A5 (OSRAM) | ||
| Noori et al. | The effect of magnesium oxide nanoparticles on the antibacterial and antibiofilm properties of glass-ionomer cement | |
| Ribeiro et al. | Dental caries and their microbiomes in children: what do we do now? | |
| Di Pierro et al. | Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media | |
| Hay et al. | Bacterial infections | |
| Schaffner et al. | A point mutation in cpsE renders Streptococcus pneumoniae nonencapsulated and enhances its growth, adherence and competence | |
| Soares et al. | Frequency of oral mucositis and microbiological analysis in children with acute lymphoblastic leukemia treated with 0.12% chlorhexidine gluconate | |
| Merkley et al. | The effect of antibiotics on the microbiome in acute exacerbations of chronic rhinosinusitis | |
| Navidinia et al. | Molecular characterization of resistance genes in MDR-ESKAPE pathogens | |
| CN111888369A (zh) | 聚糖组合物及其用途 | |
| WO2015077794A4 (en) | Synergistic bacterial compositions and methods of production and use thereof | |
| JP2011530534A5 (OSRAM) | ||
| Magnet et al. | Isolation and identification of different bacteria from different types of burn wound infections and study their antimicrobial sensitivity pattern | |
| Bhardwaj | Enterococci: an important nosocomial pathogen | |
| Zahmatkesh et al. | Effect of samarium oxide nanoparticles on virulence factors and motility of multi-drug resistant Pseudomonas aeruginosa | |
| Moskovicz et al. | Skin microbiota dynamics following B. subtilis formulation challenge: an in vivo study in mice | |
| Cho et al. | Resistance mechanisms and clinical characteristics of linezolid-resistant Enterococcus faecium isolates: a single-centre study in South Korea | |
| Perri et al. | In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin | |
| Wang et al. | Comparison of solithromycin with erythromycin in Enterococcus faecalis and Enterococcus faecium from China: antibacterial activity, clonality, resistance mechanism, and inhibition of biofilm formation | |
| Onanuga et al. | Antibiogram and virulence characteristics of multi-drug resistant Staphylococcus aureus from nasal cavity of healthy students of Niger delta university, Amassoma, Bayelsa state, Nigeria | |
| Mariano et al. | Identification and antimicrobial susceptibility profile of bacteria isolated from primary endodontic infections | |
| Chomei et al. | Long-term use of tedizolid for pulmonary nocardiosis | |
| Rajaram et al. | Streptococcus mutans levels in patients who received orthodontic brackets bonded using probiotic impregnated resin composite–a randomized clinical trial | |
| Bilska-Stokłosa et al. | Streptococcus constellatus as an aetiological factor of extensive neck phlegmon complicated by sepsis–case study |